New York-based Eyenovia develops a pipeline of late-stage microdose array print (MAP) therapeutics. It aims for this system to improve the overall patient experience and streamline practice flow.
The investigational device showed promise in delivery cleaner and more efficient ocular drug delivery, according to a news release.
“The proprietary Eyenovia device takes a novel approach to administering eye medication via microdosing and does it in a way that should improve the patient experience,” said Michael Rowe, CEO of Eyenovia. “Traditional eye droppers are cumbersome, inaccurate, and prone to contamination. Even when handled with care, there’s still a significant likelihood that medication patients are paying for gets wasted due to missing drops.”
About the Eyenovia device
Eyenovia designed the device with no protruding parts and a recessed nozzle. This allows for no touching to the patients’ eyes, reducing the likelihood of infection.
Additionally, the company anticipates a more gentle dosing experience with the device. It said this could create a fundamental paradigm shift in eye care.
The company said eye drop innovation “has stagnated.” This comes as a result of changing medical device regulations, Eyenovia noted. It expects regulators to “keep pace with the cutting-edge new products” pushing the boundaries of digital technology.
“We’re proud to be innovating in this space where we have the potential to make lives easier for millions of Americans and people worldwide suffering from chronic eye conditions,” said Rowe.
